文献速递临床试验与 GCP

比较兰地洛尔与胺碘酮治疗心脏术后新发心房颤动的FAAC试验:随机对照试验研究方案

Comparison of landiolol and amiodarone for the treatment of new-onset atrial fibrillation after cardiac surgery (FAAC) trial: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2023-05-25

心脏术后心房颤动(PoAF)发生率高达30%,但管理存在争议。FAAC试验为多中心单盲两平行组随机研究,计划纳入350例心脏术后首次PoAF患者,比较兰地洛尔与胺碘酮在48小时内恢复窦性心律的比例,假设兰地洛尔组恢复比例从70%提高至85%。

要点

  • FAAC试验计划纳入350例心脏术后首次PoAF患者,随机分为兰地洛尔组和胺碘酮组。
  • 主要假设为兰地洛尔在PoAF发作后48小时内恢复窦性心律的比例从70%提高至85%。
  • 若兰地洛尔恢复窦性心律比例更高,该β受体阻滞剂可能成为此情境下的首选药物,以减少抗凝治疗需求及并发症风险。

核心结论

  • 兰地洛尔与胺碘酮在心脏术后新发心房颤动治疗中的比较尚缺乏随机对照证据,FAAC试验旨在验证兰地洛尔在48小时内恢复窦性心律的比例是否优于胺碘酮。

研究设计与样本

  • FAAC试验为多中心、单盲、两平行组随机对照研究,计划纳入350例心脏术后首次发生PoAF的患者,研究周期2年。

主要发现

  • 原文未报告结果。

关键数值与推荐

  • 在纠正低血容量、血钾异常及床旁经胸超声心动图确认无心包积液后,若PoAF持续至少30分钟,由负责麻醉医生通过Ennov Clinical®进行随机化。
  • 样本量计算基于兰地洛尔组48小时内恢复窦性心律比例从70%提高至85%的假设,α风险=5%,把握度=90%,双侧检验。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postoperative atrial fibrillation (PoAF) after cardiac surgery has a high incidence of 30%, but its management is controversial. Two strategies are recommended without evidence of a superiority of one against the other: rate control with beta-blocker or rhythm control with amiodarone. Landiolol is a new-generation beta-blocker with fast onset and short half-life. One retrospective, single-center study compared landiolol to amiodarone for PoAF after cardiac surgery with a better hemodynamic stability and a higher rate of reduction to sinus rhythm with landiolol, justifying the need for a multicenter randomized controlled trial. Our aim is to compare landiolol to amiodarone in the setting of PoAF after cardiac surgery with the hypothesis of a higher rate of reduction to sinus rhythm with landiolol during the 48 h after the first episode of POAF. METHODS: The FAAC trial is a multicenter single-blind two parallel-arm randomized study, which planned to include 350 patients with a first episode of PoAF following cardiac surgery. The duration of the study is 2 years. The patients are randomized in two arms: a landiolol group and an amiodarone group. Randomization (Ennov Clinical®) is performed by the anesthesiologist in charge of the patient if PoAF is persistent for at least 30 min after correction of hypovolemia, dyskalemia, and absence of pericardial effusion on a transthoracic echocardiography done at bedside. Our hypothesis is an increase of the percentage of patients in sinus rhythm from 70 to 85% with landiolol in less than 48 h after onset of PoAF (alpha risk = 5%, power = 90%, bilateral test). DISCUSSION: The FAAC trial was approved by the Ethics Committee of EST III with approval number 19.05.08. The FAAC trial is the first randomized controlled trial comparing landiolol to amiodarone for PoAF after cardiac surgery. In case of higher rate of reduction with landiolol, this beta-blocker could be the drug of choice used in this context as to reduce the need for anticoagulant therapy and reduce the risk of complications of anticoagulant therapy for patients with a first episode of postoperative atrial fibrillation after cardiac surgery. TRIAL REGISTRATION: ClinicalTrials.gov NCT04223739. Registered on January 10, 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Caspersen E, Guinot PG, Rozec B, et al. Comparison of landiolol and amiodarone for the treatment of new-onset atrial fibrillation after cardiac surgery (FAAC) trial: study protocol for a randomized controlled trial. Trials. 2023. PMID: 37226174. doi:10.1186/s13063-023-07353-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。